In vitro studies on the biochemistry and pharmacology of low molecular weight heparins

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 27-33

  Jeske, Walter ^a,b   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Cardiovascular Institute   (United States)

Author keywords

Biochemistry; In vitro; Low molecular weight heparin; Pharmacology

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PLASMA PROTEIN; REVIPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBIN TIME; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DRUG EVALUATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032743492     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304
2. Frydman A. Low molecular weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996:26(Suppl 2):24-38
3. Linhardt RJ, Loganathan D, Al-Hakim A, et al. Oligosaccharide mapping of low molecular weight heparins: Structure and activity differences. J Med Chem 1990;33:1639-1645
4. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Haemostasis 1988;18(Suppl3):3-15
5. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: A developmental perspective. Exp Opin Invest Drugs 1997;6:705-733
6. Houbouyan L, Padilla A, Gray E, Longstaff C, Barrowcliffe TW. Inhibition of thrombin generation by heparin and LMW heparins: A comparison of chromogenic and clotting methods. Blood Coag Fibrinolysis I996;7:24-30
7. Mauray S, de Rancourt E, Talbot J-C, et al. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan. Biochim BiophysActa 1998;1387:184-194
8. DeCristofaro R, De Candia E, Landolfi R. Effect of high and low molecular weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation I998;98:1297-1301